China's Yisheng moves forward with rabies vaccine in U.S.
By Pearl Liu
Wednesday, January 11, 2017
HONG KONG – Beijing-based Yisheng Biopharma Co. Ltd. said the recent U.S. FDA orphan designation for its PIKA rabies orphan drug is another milestone in its push to expand outside of China.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.